Comments on: Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Comments on: Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist https://9krapalm.com/ascletis-announces-positive-interim-results-from-its-u-s-phase-ib-trial-with-asc30-a-potentially-first-in-class-subcutaneous-injection-small-molecule-glp-1r-agonist/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Mon, 31 Mar 2025 11:44:05 +0000 hourly 1 https://wordpress.org/?v=7.0